SHORT-COURSE PALLIATIVE RADIATION THERAPY FOR ADVANCED H&N TUMORS: FINAL RESULTS OF A PHASE II STUDY

F. Deodato[1], L. Caravatta[2], J. Capuccini[3], G. Torre[1], A. Farioli[4], M. Buwenge[3], G. Macchia[1], S. Cilla[5], W. Tigeneh[6], A. F. M. Kamal Uddin[7], M.A. Sumon[7], T. Salah[8], D. Dawotola[9], A. A. Woldemariam[6], P. A. Banu[10], E. Farina[3], A. Arcelli[3], F. Bertini[3], S. Cammelli[3], S. Mignogna[11], G. P. Frezza[12], V. Valentini[1, 13], A. G. Morganti[3].

[1]Radiotherapy Unit, Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy; [2]Radiotherapy Unit, Centro di Radioterapia e Medicina Nucleare, P.O. Businco, Cagliari, Italy; [3]Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Bologna, Italy; [4]Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, Italy; [5]Medical Physics Unit, Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy; [6]Department of Radiotherapy, Black Lion Hospital, Addis Ababa, Ethiopia; [7]Radiation Oncology Department, United Hospital Limited, Gulshan, Dhaka, Bangladesh; [8]Faculty of Medicine, Assiut University, Assiut, Egypt; [9]Department of Radiotherapy, Radiotherapy and Oncology Centre, Abuth, Zaria, Nigeria; [10]Radiation Oncology Department, Delta Medical Center, Dhaka, Bangladesh; [11]General Oncology Unit, Fondazione di Ricerca e Cura "Giovanni Paolo II", Campobasso, Italy; [12]Radiotherapy Department, Ospedale Bellaria, Bologna, Italy; [13]Department of Radiotherapy, Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Roma, Italy

francesco.deodato@fgps.it

Associazione Italiana Radioterapia Oncologica
Società Italiana di Radiobiologia
Farmaci innovativi e ipofrazionamento
PALACONGRESSI DI RIMINI
30 settembre, 1-2 ottobre 2016

Patients treated for **symptom palliation** commonly have:

- **limited survival**,
- **physical discomfort** with transportation,
- and **emotional disdain** for **prolonged treatment** courses.

A **shorter treatment** could offer a considerable **simplification** in palliative care: most patients **will not survive to face** the increased risk of **long-term side effects** associated with hypofractionated regimens.

Società Italiana di Radiobiologia
MATERIALE NON RIPRODUCIBILE

Associazione Italiana Radioterapia Oncologica
Società Italiana di Radiobiologia
Farmaci innovativi e ipofrazionamento
PALACONGRESSI DI RIMINI
30 settembre, 1-2 ottobre 2016

SHort course **A**ccelerated **R**adiati**ON** therapy **= SHARON**

2 daily fractions over 2 days

reduction of total treatment **time**

improving the physical and psychological **comfort**

faster **resolution** of clinical **symptoms**

possibility of **retreatment**

Società Italiana di Radiobiologia MATERIALE NON RIPRODUCIBILE

Associazione Italiana Radioterapia Oncologica
Società Italiana di Radiobiologia
Farmaci innovativi e ipofrazionamento
PALACONGRESSI DI RIMINI
30 settembre, 1-2 ottobre 2016

To assess the effectiveness of a SHort-course Accelerated RadiatiON therapy (SHARON) in the palliative treatment of patients with advanced primary or metastatic H&N tumors

MATERIALE NON RIPRODUCIBILE

Phase II clinical trial (Two- stage Simon's design)

- *23 patients with advanced primary or metastatic H&N cancer*
- *ECOG ≤ 3*
- *RT dose schedule: 20 Gy/5 Gy BID*

Primary endpoint:

to assess efficacy in terms of symptoms relief

Società Italiana di Radiobiologia
MATERIALE NON RIPRODUCIBILE

Associazione Italiana Radioterapia Oncologica
Società Italiana di Radiobiologia
Farmaci innovativi e ipofrazionamento
PALACONGRESSI DI RIMINI
30 settembre, 1-2 ottobre 2016

Results (23 patients)



Overall palliative response rate: 91,3%

SVV3m: 89.7%
Median SPFS: 5m
(95%CI: 1.8-8.1)

Median age: 83 (40-98)

ECOG < 3: 11 pts (47.8%)

Median F-Up: 4 months (1-32)

Acute Toxicity	%
Skin G1-2	60,9
Mucositis G1-2	39,1
Mucositis G3	4,3
Late Toxicity	**%**
Skin G1	13,0
Skin G2	4,3

Società Italiana di Radiobiologia MATERIALE NON RIPRODUCIBILE

Results





MATERIALE NON RIPRODUCIBILE

Associazione Italiana Radioterapia Oncologica
Società Italiana di Radiobiologia
Farmaci innovativi e ipofrazionamento
PALACONGRESSI DI RIMINI
30 settembre, 1-2 ottobre 2016

- **Short-course accelerated H&N radiotherapy (20 Gy in twice daily fractions for 2 consecutive days) is tolerated and effective in terms of symptom relief.**

- **A phase III comparison against a standard palliative regimen (30 Gy in 10 fractions) has been planned in this patient population.**

Società Italiana di Radiobiologia
MATERIALE NON RIPRODUCIBILE

Associazione Italiana Radioterapia Oncologica
Società Italiana di Radioterapia Oncologica
MATERIALE NON RIPRODUCIBILE